Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224125 | 0.91 | USP2 (0.44) | HPGDUSP2SMN1; SMN2PDK2RORC | |
| SCHEMBL31080187 | 0.88 | HPGD (0.46) | HPGDUSP2SMN1; SMN2MAPTMEN1 | |
| SCHEMBL3506743 | 0.84 | USP2 (0.44) | HPGDUSP2SMN1; SMN2MAPTPDK2 | |
| SCHEMBL2706445 | 0.81 | USP2 (0.50) | HPGDUSP2SMN1; SMN2MAPTMEN1 | |
| SCHEMBL24095376 | 0.80 | HPGD (0.45) | HPGDUSP2SMN1; SMN2MAPTMEN1 | |
| SCHEMBL1262593 | 0.80 | HPGD (0.45) | HPGDUSP2SMN1; SMN2MAPTMEN1 | |
| SCHEMBL3940936 | 0.80 | HPGD (0.45) | HPGDUSP2SMN1; SMN2MAPTMEN1 | |
| SCHEMBL24711544 | 0.80 | HPGD (0.45) | HPGDUSP2SMN1; SMN2MAPTMEN1 | |
| SCHEMBL21301106 | 0.79 | HPGD (0.40) | HPGDUSP2SMN1; SMN2MAPTMEN1 | |
| SCHEMBL4439843 | 0.79 | USP2 (0.40) | HPGDUSP2SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046714-B2 | 2,2-difluorodioxolo A2A receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3038466-B1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-2566859-B1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO LTD (KR) | 2016-12-21 | — | — | EP | disclosed |
| US-20160214997-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-07-28 | — | — | US | disclosed |
| EP-3038466-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9096571-B2 | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2566859-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Sk Chemicals Co., Ltd. (KR) | 2013-03-13 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| WO-2011139107-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO.,LTD. (KR) | 2011-11-10 | — | — | WO | disclosed |
| CN-101679266-A | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | HPGD 3395/4885USP2 4/4885SMN1; SMN2 3154/4885 |
| US-11046714-B2 | 2,2-difluorodioxolo A2A receptor antagonists | ADORA2A, ADORA2B, ADORA3 | HPGD 1324/4885USP2 2692/4885SMN1; SMN2 701/4885 |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | HPGD 3395/4885USP2 4/4885SMN1; SMN2 3154/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | HPGD 3004/4885USP2 3414/4885SMN1; SMN2 2557/4885 |
| US-20160214997-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | HPGD 1324/4885USP2 2692/4885SMN1; SMN2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.